13274
document
Prevention of coronary spasm by nicorandil : comparison with nifedipine . The efficacy of nicorandil was compared with that of nifedipine in 13 patients with vasospastic angina enrolled in a randomized , placebo-controlled , crossover study . All patients had a coronary spasm during coronary arteriography , either spontaneously or ergometrine-induced . During two consecutive periods of 2 days , patients received active drugs or placebo in a randomized order . Each patient received single oral doses of 30 mg nicorandil , 10 mg nifedipine , and , on 2 days , a placebo . One hour after drug intake , patients underwent an ergometrine test with increasing doses of Methergin ( ergometrine ) ( 0.05 , 0.10 , 0.20 , and 0.40 mg every 5 min ) . After placebo , the tests always were positive , and the ECG changes occurred at the same +/- 1 dose of ergometrine in 10 cases , showing good reproducibility . After nicorandil , the tests were negative in nine patients and positive for a higher or lower dose of ergometrine in three and one patient , respectively ( p = 0.0034 vs. placebo ) . After nifedipine , the tests were negative in five patients and positive for a higher or the same dose of ergometrine in four and four patients , respectively ( p = 0.0039 vs. placebo ) . Nifedipine ( 10 mg ) and nicorandil ( 30 mg ) were equally effective in eight patients ; in the remaining five patients , nicorandil had better results ( p = 0.06 ) . Nicorandil ( 30 mg ) prevents ergometrine-induced coronary spasm . This compound may be beneficial in patients with vasospastic angina .
13275
Intervention_Pharmacological
nicorandil :
13276
Intervention_Pharmacological
nifedipine .
13277
Intervention_Pharmacological
nicorandil
13278
Intervention_Pharmacological
nifedipine
13279
Intervention_Psychological
placebo-controlled
13280
Intervention_Pharmacological
active drugs
13281
Intervention_Pharmacological
placebo
13282
Intervention_Pharmacological
nicorandil
13283
Intervention_Pharmacological
nifedipine
13284
Intervention_Pharmacological
placebo
13285
Intervention_Pharmacological
Methergin ( ergometrine )
13286
Intervention_Pharmacological
placebo
13287
Intervention_Pharmacological
ergometrine
13288
Intervention_Pharmacological
nicorandil
13289
Intervention_Pharmacological
ergometrine
13290
Intervention_Pharmacological
placebo )
13291
Intervention_Pharmacological
nifedipine
13292
Intervention_Pharmacological
ergometrine
13293
Intervention_Pharmacological
placebo
13294
Intervention_Pharmacological
Nifedipine
13295
Intervention_Pharmacological
nicorandil
13296
Intervention_Pharmacological
Nicorandil
13297
Outcome_Other
ECG changes
13298
Outcome_Physical
ergometrine-induced coronary spasm
13299
Outcome_Physical
vasospastic angina
13300
Participant_Condition
coronary spasm
13301
Participant_Sample-size
13
13302
Participant_Condition
vasospastic angina
13303
Participant_Condition
coronary spasm
13304
Participant_Condition
coronary arteriography
13305
Participant_Condition
vasospastic angina